Evidence map›Paper›PMID 32290154›Full record

ArticleNanomaterials (Basel, Switzerland)2020

Improving Anticancer Therapy with Naringenin-Loaded Silk Fibroin Nanoparticles.

Marta G Fuster, Guzmán Carissimi, Mercedes G Montalbán, Gloria Víllora

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Clinical progress and prospects of biodegradable intestinal stents.American journal of translational research · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Naringenin Nanoformulations for Neurodegenerative Diseases.Current pharmaceutical biotechnology · 2024
    Review
  8. Advances in Preparation and Properties of Regenerated Silk Fibroin.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Flavonoids-Based Delivery Systems towards Cancer Therapies.Bioengineering (Basel, Switzerland) · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marta G FusterDepartment of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.
Guzmán CarissimiDepartment of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.
Mercedes G MontalbánDepartment of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.ORCID 0000-0003-1085-3042
Gloria VílloraDepartment of Chemical Engineering, Faculty of Chemistry, University of Murcia (UMU), Campus de Espinardo, 30100 Murcia, Spain.

Funding

Fundación Séneca 20977/PI/18Ministerio de Economía, Industria y Competitividad, Gobierno de España CTQ2017-87708-RMinisterio de Economía, Industria y Competitividad, Gobierno de España PRE2018-086441
6 · The paper itself

Abstract

Naringenin (NAR), a flavonoid present in a variety of fruits, vegetables and herbs, exhibits a wide range of pharmacological effects, including anticancer activity. Nevertheless, its application in cancer therapy is limited due to its low bioavailability at the tumour site because of its poor solubility in water and slow dissolution rate. To improve the therapeutic efficacy of NAR, emergent research is looking into using nanocarriers. Silk fibroin (SF), from the

Indexed as

anticancer activitycytotoxicitygreen synthesisionic liquidsnanoparticlenaringeninsilk fibroin

Identifiers

PMID32290154
PMCPMC7221656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.